Movement Alert｜Guardant Health Inc. Falls 5.36% in Regular Trading, Profit-Taking After Multi-Catalyst Rally

Market Focus10-06 22:13

On October 6, Guardant Health Inc. fell 5.36% in regular trading, trading at $177.2 per share with turnover of $118 million. The decline followed a prior-session gain of 5.30% that pushed the stock to a 52-week high of $187.69, suggesting a technical pullback driven by profit-taking.

UBS recently raised its price target to $225 from $175 and maintained a Buy rating, citing AstraZeneca's Serena-4 trial failure as validation of the liquid biopsy technology route. Additional positive catalysts included the inclusion of the company's colorectal cancer screening test in Evicore coverage and FDA approval of a breast cancer companion diagnostic.

Guardant Health Inc. is a precision oncology company providing blood-based tests, data sets, and analytics for cancer screening, recurrence monitoring, and treatment selection.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment